These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35758508)

  • 21. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?
    Oppong BA; Rolle AA; Ndumele A; Li Y; Fisher JL; Bhattacharyya O; Adeyanju T; Paskett ED
    Breast Cancer Res Treat; 2022 Nov; 196(2):399-408. PubMed ID: 36152139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study.
    Llanos AA; Chandwani S; Bandera EV; Hirshfield KM; Lin Y; Ambrosone CB; Demissie K
    Cancer Causes Control; 2015 Dec; 26(12):1737-50. PubMed ID: 26376894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
    Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
    Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States.
    Moore J; Pal T; Beeghly-Fadiel A; Fadden MK; Munro HM; Dujon SA; Reid S; Tezak A; Blasingame M; Ware J; Blot WJ; Shu XO; Zheng W; Sanderson M; Lipworth L
    Cancer Causes Control; 2022 Apr; 33(4):515-524. PubMed ID: 35088206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer.
    Sheppard VB; Cavalli LR; Dash C; Kanaan YM; Dilawari AA; Horton S; Makambi KH
    Clin Breast Cancer; 2017 Jun; 17(3):232-238. PubMed ID: 28189497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
    Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer.
    Hercules SM; Hercules JC; Ansari A; Date SAJ; Skeete DHA; Smith Connell SP; Pond GR; Daniel JM
    Cancer; 2020 May; 126(10):2217-2224. PubMed ID: 32154924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations Between Neighborhood-Level Income and Triple-Negative Breast Cancer in a Majority-Minority Population.
    Hernandez AE; Westrick AC; Stoler J; Kesmodel SB; Pinheiro PS; Figueroa M; Kobetz EN; Rebbeck T; Goel N
    Ann Surg Oncol; 2024 Feb; 31(2):988-996. PubMed ID: 37978105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Duan L; Lu Y; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2017 Jan; 19(1):6. PubMed ID: 28086982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
    Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
    McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
    Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the Southeastern United States.
    Sanderson M; Pal T; Beeghly-Fadiel A; Fadden MK; Dujon SA; Clinton C; Jimenez C; Davis J; Fortune M; Thompson J; Benson K; Conley N; Reid S; Tezak A; Shu XO; Zheng W; Blot WJ; Lipworth L
    Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1416-1423. PubMed ID: 33947654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
    Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
    Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors.
    Prakash O; Hossain F; Danos D; Lassak A; Scribner R; Miele L
    Front Public Health; 2020; 8():576964. PubMed ID: 33415093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A majority of circadian clock genes are expressed in estrogen receptor and progesterone receptor status-dependent manner in breast cancer.
    Berkel C; Cacan E
    J Biosci; 2024; 49():. PubMed ID: 39193850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.